| Today's Big NewsJun 9, 2023 |
|
Wednesday, Jun 14, 2023 | 10:00am ET / 7:00am PT Targeting proteins for degradation therapeutically, as an alternative to inhibiting them, holds great promise for treating diseases in which pathogenic proteins are considered "undruggable" due to a lack of active sites for conventional small molecules. Register now.
|
|
| By Eric Sagonowsky After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing. |
|
|
|
By Max Bayer Lilly is aware of and “closely looking into” anecdotes that patients taking GLP-1 drugs seem to have an easier time quitting alcohol or cigarettes—but proving a genuine impact is easier said than done. |
By James Waldron Vertex and CRISPR Therapeutics’ dream of getting the first-ever CRISPR gene editing therapy approved now seems within reach as the candidate aced primary endpoints in a pair of phase 3 trials mere hours after the FDA penciled in a decision date for December. |
By Andrea Park Just a few months after expanding its respiratory and anesthesia device portfolio by purchasing some of Vyaire Medical’s hardware, medtech manufacturer SunMed is shining its light on yet another acquisition target. |
|
Thursday, June 15, 2023 | 11am ET / 8am PT In this era of personalized medicine, biomarkers can provide important insights at every stage of drug discovery and development. By advancing our understanding of cancer pathophysiology and tumor profiling, they play a critical role in the rational development of novel therapies. Register now to learn more.
|
|
By Nick Paul Taylor Editas Medicine has shared early clinical data on the cell therapy it is developing to challenge Vertex and CRISPR Therapeutics for the sickle cell market. The CRISPR-edited therapy showed clear signs of efficacy, but, with its rivals awaiting FDA approval, differentiating a late-to-market challenger could be tough. |
By Kevin Dunleavy Bristol Myers Squibb took a positive step toward beefing up its cell therapy manufacturing capabilities as the FDA gave the go-ahead for the company to begin commercial production at its sprawling facility in Devens, Mass. |
By Teresa Carey This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
By Zoey Becker After Merck's bombshell lawsuit contesting the Inflation Reduction Act, shareholders at the Interfaith Center on Corporate Responsibility are asking the company to reconsider. They're citing Merck's stated commitments to access and affordability as the rationale behind their plea. |
By Andrea Park The FoundationOne Liquid CDx test's 10th approval allows it to be used to pair patients with a combination of Pfizer’s encorafenib, marketed under the name Braftovi, and the cancer drug cetuximab, sold as Erbitux by Eli Lilly in the U.S. |
By Eric Sagonowsky Seeking to launch their RSV prevention antibody for infants later this year, Sanofi and AstraZeneca have cleared one more regulatory hurdle. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines. |
|
|---|
|
|
|
Tuesday, June 27, 2023 | 2:00pm ET / 11:00am PT In this webinar we will discuss the growing complexity of clinical research, examples of how eClinical tools can reduce human effort, streamlining the time to approval, current challenges and gaps in eClinical tech, and more. Register now.
|
|
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
